Loss of Single-Domain Function in a Modular Assembly Line Alters the Size and Shape of a Complex Polyketide

Huiyun Peng, Keishi Ishida, and Christian Hertweck*

Abstract: The structural wealth of complex polyketide metabolites produced by bacteria results from intricate, highly evolved biosynthetic programs of modular assembly lines, in which the number of modules defines the size of the backbone, and the domain composition controls the degree of functionalization. We report a remarkable case where polyketide chain length and scaffold depend on the function of a single β-keto processing domain: A ketoreductase domain represents a switch between diverging biosynthetic pathways leading either to the antifungal aureothin or to the nematicidal luteoreticulin. By a combination of heterologous expression, mutagenesis, metabolite analyses, and in vitro biotransformation we elucidate the factors governing non-colinear polyketide assembly involving module skipping and demonstrate that a simple point mutation in type I polyketide synthase (PKS) can have a dramatic effect on the metabolic profile. This finding sheds new light on possible evolutionary scenarios and may inspire future synthetic biology approaches.

Modular type I polyketide synthases (PKSs) assemble a broad range of ecologically and pharmaceutically relevant molecules.[1] In contrast to the chemical synthesis of complex polyketides, which often requires challenging, multistep transformations,[2] type I PKSs connect and process simple acyl and malonyl thioester building blocks in a fully programmed fashion.[3] Structural diversity results from variations in the biosynthetic program. Typically, an activated starter unit is loaded onto the PKS and propagated by modules that minimally consist of a ketosynthase (KS) domain catalyzing a Claisen condensation for C–C bond formation, an acyltransferase (AT) domain selecting and loading the malonyl extender unit, and an acyl carrier protein (ACP) domain serving as an anchor for the growing acyl chain. The polyketide chain is passed from one module to another until it is released from the PKS, usually catalyzed by a thioesterase (TE) domain.[3] In each module optional ketoreductase (KR), dehydrogenase (DH), and enoylreductase (ER) domains determine to which degree the β-keto groups of the intermediates are processed. Owing to the unidirectional propagation of the nascent chain bound to the assembly lines, the structures of the polyketide backbones and the corresponding modular PKSs are typically colinear.[3] Thus, it is generally feasible to predict the basic polyketide structures based on the number and architectures of the PKS modules, and vice versa. (Figure 1) This co-linearity rule has been successfully applied for genome mining[4] and rational biosynthetic engineering approaches.[5] Furthermore, it provides a model for the evolution of polyketide diversity: whereas gene duplications or deletions would lead to different chain lengths (number of modules), the gain or loss of encoded domain functions would influence the degree of β-keto processing (composition of modules).[6]

To gain insight into such evolutionary processes and to emulate possible recombination scenarios we have studied in detail the biosynthesis of structurally related bacterial polyketides that share characteristic nitroaryl and pyrone moieties.[7] Functional analyses of the assembly lines for the prototype of this family, the antifungal and antiproliferative agent aureothin ([aur, 1]) and a higher homologue, neo-aureothin (syn. spectinabilin),[9] revealed that the involved PKSs breach with the co-linearity rule.[10] Specifically, the first modules and the penultimate AT domains are used itera-
tively. Based on the deduced biosynthetic program of the *aur* PKS we have engineered an artificial pathway for the nematicide luteoreticulin ([syn. griseulin](13) 2). This congener has a reduced chain length compared to 1, an isomeric pyrone ring, and an altered substitution pattern. Although it has been feasible to morph the *aur* PKS into an artificial luteoreticulin (alut) assembly line (Supporting Information, Figure S1) in the plethora of sequenced bacterial genomes a genuine gene cluster coding for luteoreticulin biosynthesis has not yet been detected. Here we elucidate the true biosynthetic origin of luteoreticulin and show the unexpected impact of single loss-of-function mutations of a modular PKS on the metabolite scaffold.

Prompted by the surprising observation that the aureothin producer strain *Streptomyces thioluteus* produces minute amounts of 2, we revisited reported luteoreticulin producers (*S. luteoreticuli* [12] and *S. griseus* [15]) and noted that 1 was also detected in their fermentation broths. To test the possibility that 2 is a side product of the *aur* pathway we investigated a heterologous host exclusively expressing the *aur* biosynthesis gene cluster (*S. albus*::pHJ48). By metabolic profiling of an up-scaled culture of this designated producer strain we detected small amounts of 2. Given that both polyketide metabolites (1 and 2) differ in both size and shape, it is remarkable that they seem to derive from the same modular assembly line.

The formation of 2 as a byproduct of the *aur* PKS (Figure 2B) could be rationalized by erratic substrate processing or by non-functional catalytic domains. A retro-biosynthetic analysis suggested that the pyrone ring would result from the cyclization of an enol intermediate. The requisite carbonyl group would require an impaired β-keto reduction after three rounds of elongations. Thus, we postulated that the ketoreductase domain (KR2) in module 2 (*AurB*) constitutes a branching point for the *lut* and *aur* pathways.

To probe this hypothesis we scrutinized the KR2 domain. Alignment with other known KR domains (Figure S2) indicated that KR2 belongs to B1-type KRs, which are characterized by a diagnostic LDD motif (VDĐ in KR2) and the absence of a Trp eight residues upstream of the catalytic Tyr. We also identified the catalytic Lys, Tyr, and Ser moieties that aid in binding and reducing polyketide intermediates. The only deviation is that leucine is replaced by Val in the conserved LDD motif. However, this replacement occasionally appears in other active KR domains (e.g., Nys3 and Nys12, Figure S2) and is thus unlikely to influence the reductive activity. Since KR2 is obviously functional, an impaired β-keto reduction could result from a limited supply of the essential cofactor NADPH or from a slow turnover rate.

To test whether a complete shutdown of KR2 has an impact on the production of 2, we inactivated the KR2 domain. Therefore, we replaced tyrosine with phenylalanine in the catalytic motif YAAN by site-directed mutagenesis of the PKS gene cloned into plasmid pHJ48 (Figures 2B and S3). The resulting mutated plasmid (pHY127) was introduced into expression host *S. albus* by conjugation to generate the KR2 null mutant (*S. albus*::pHY127).

The metabolic profiles of *S. albus*::pHY127 and *S. albus*::pHJ48 were compared. A strong yellow pigmentation indicated an altered metabolite spectrum of the KR2 null mutant (Figure 2C). HPLC-MS analyses of the culture extracts showed that the production of 2 increased dramatically in the KR2 null mutant (50.8 mg L⁻¹), whereas 1 could only be detected in trace amounts (0.36 mg L⁻¹) (Figure 2D, trace iv and Figure S7). Notably, production of 2 in the KR2 null mutant was 500-fold higher than in the strain with the artificial *lut* (alut) PKS (0.1 mg L⁻¹) [14]. This finding strongly suggests that luteoreticulin production could result from a single loss of function in *AurB*. As a consequence of the impaired ketoreduction in module 2 the polyketide intermediate obviously skips a downstream module.

To gain insight into the impact of incomplete β-keto processing we generated two additional mutants, one that is deficient in dehydration, and another one that lacks a func-
tional ER domain. Therefore, we replaced the catalytic His of the HVVLGSTLVP motif\(^{[3a]}\) of DH2 by Phe, yielding DH2 null mutant \(S.\) \textit{albus::pHY140} (Figure S4). To obtain the ER2 null mutant, \(S.\) \textit{albus::pHY147} (Figure S5), we changed the conserved NADPH-binding motif GGVGMA\(^{[3a]}\) to SPVGMA in ER2. HPLC analysis of the metabolic profile of the DH2 null mutant showed that in lieu of 1 and 2, which can only be detected in trace amounts, several new compounds (3–5) are produced (Figure 3B, trace iii). These metabolites were isolated in pure form by preparative HPLC to obtain 3 (6.4 mg), 4 (24.7 mg), and 5 (3.6 mg) from 1 L culture of DH2 null mutant (\(S.\) \textit{albus::pHY140)), and their structures were elucidated by 1D and 2D NMR analysis (Figure 3A, Figures S8–S28, and Tables S1–S3). The absolute configurations of 3 and 4 were determined by the combination of in silico analyses\(^{[17]}\) and chemical derivatization (Figures S29–S43, Tables S4–S6).

In agreement with the domain set of the mutated module 2 (DH2 null), compound 3 is a congener of 1 with a hydroxyl group at C8 that results from incomplete \(\beta\)-keto processing. Compound 4 has an additional hydroxyl group at C7, which is likely introduced by the cytochrome P450 monooxygenase AurH\(^{[18]}\). Compound 5 differs from 3 in a keto group at C8. This keto group might result from a) impaired ketoreduction, or b) oxidation of 3, possibly by AurH. To elucidate the biogenesis of these oxygenated compounds, we heterologously produced AurH in \(E.\) \textit{coli} used recombinant AurH for biotransformation experiments. In vitro assays showed that AurH transforms 3 into 4 and 5 (Figures 3C and S58). Consequently, 4 results from AurH-mediated \(\gamma\)-hydroxylatation, and 5 is formed by the oxidative route,\(^{[19]}\) which is plausible since an impaired KR at this stage would channel the intermediate into the \(\text{lut}\) pathway.

From the HPLC profile of the ER2 null mutant, we detected two new compounds, 6 and 7 (Figure 3B, trace vi). The structures of 6 and 7 were determined by 1D and 2D NMR analyses of the isolated and purified compounds (Figures 3A and S44–S57, and Tables S7 and S8). Both 6 and 7 feature double bonds at the respective C7–C8 positions that result from ketoreduction and dehydratation, and differ only in the configuration of the O-methylated pyrone ring (\(\alpha\)- or \(\gamma\)-position), which is mediated by the methyltransferase AurI\(^{[20]}\). It is remarkable that trace amounts of 2 are detectable in all mutants. The formation of 2 can be explained by the non-quantitative reduction of the \(\beta\)-keto group in module 2 as observed in the wild-type PKS (\(S.\) \textit{albus::pHJ48}). Traces of 1 in the DH2 null mutant can be explained by non-enzymatic dehydration of the hydroxy intermediate, or by the involvement of a long-range acting DH domain as in isomigrastatin biosynthesis.\(^{[21]}\)

The key message of these mutational experiments is, however, that the biosynthesis of 2 primarily depends on the dysfunction of the KR. Furthermore, it is remarkable that no module skipping takes place when the \(\beta\)-keto group is processed into either \(\beta\)-hydroxyl or enoyl groups. This finding indicates that the unreduced \(\beta\)-keto group in module 2 is essential for the skipping process required for \(\text{lut}\) biosynthesis. Since AT4 is smaller than typical AT domains, and the function of AT4 can be substituted by AT3 from the penultimate module,\(^{[14]}\) module 4 is likely skipped.
To test this hypothesis, we replaced AT4 with AT3 in the KR2 null mutant. HPLC-MS analysis revealed that 2 was still produced as the main product of the KR2 null + aAT4 mutant ($S.\text{albus}$::pHY145) (Figures 4A–C and S6). Consequently, the AT domain exchange does not affect the skipping of the fourth module (Figure 4C and D). A plausible explanation for this observation is that the KS4 domain solely plays a role as a gatekeeper that recognizes the structure of the polyketide chain. The required $\beta,\delta$-diketo thioester intermediate for pyrone formation could be generated by the iterative use of module 3 (aur pathway) or by the sequential single elongation of mutated module 2 and module 3 (lut pathway). While substrate specificities of KS domains are best studied for trans-AT PKSs,[23] it is astonishing that the aur KS2 domain downstream of iterative module 1 exhibits a similar gatekeeping function.[24]

Acknowledgements

We thank Dr. Y. Sugimoto for helpful discussions, A. Perner and H. Heinecke for HRMS and NMR measurements, and the China Scholarship Council (CSC, for H.P.) and the DFG (Leibniz award for C.H.) for financial support.

Conflict of interest

The authors declare no conflict of interest.

Keywords: biosynthesis · module skipping · natural products · polyketide synthases · synthetic biology

How to cite: Angew. Chem. Int. Ed. 2019, 58, 18252–18256. Angew. Chem. 2019, 131, 18420–18424

[1] a) C. Hertweck, Angew. Chem. Int. Ed. 2009, 48, 4688–4716; Angew. Chem. 2009, 121, 4782–4811; b) J. L. Meier, M. D. Burkart, Chem. Soc. Rev. 2009, 38, 2012–2045; c) A. T. Keatinge-Clay, Chem. Rev. 2017, 117, 5334–5366.
[2] I. Paterson, N. Y. S. Lam, J. Antibiot. 2018, 71, 215.
[3] a) A. T. Keatinge-Clay, Nat. Prod. Rep. 2012, 29, 1050–1073; b) M. E. Horsman, T. F. Hari, C. N. Boddy, Nat. Prod. Rep. 2016, 33, 183–202.
[4] E. J. Helfrich, S. Reiter, J. Piel, Curr. Opin. Biotechnol. 2014, 29, 107–115.
[5] a) K. J. Weissman, Nat. Prod. Rep. 2016, 33, 203–230; b) C. Hertweck, Trends Biochem. Sci. 2015, 40, 189–199; c) C. Khosla, S. Kapur, D. E. Cane, Curr. Opin. Chem. Biol. 2009, 13, 135–143.
[6] a) H. Jenke-Kodama, A. Sandmann, R. Müller, E. Dittmann, Mol. Biol. Evol. 2005, 22, 2027–2039; b) H. Jenke-Kodama, E. Dittmann, Phytochemistry 2009, 70, 1858–1866; c) H. Wang, K. Sivonen, D. P. Fewer, Curr. Opin. Genet. Dev. 2015, 35, 79–85.
[7] a) J. He, C. Hertweck, Chem. Biol. 2003, 10, 1225–1232; b) N. Traitecheva, H. Jenke-Kodama, J. He, E. Dittmann, C. Hertweck, ChemBioChem 2007, 8, 1841–1849; c) Y. Sugimoto, K. Ishida, N. Traitecheva, B. Busch, H. M. Dahse, C. Hertweck, Chem. Biol. 2015, 22, 229–240; d) H. Peng, K. Ishida, Y. Sugimoto, H. Jenke-Kodama, C. Hertweck, Nat. Commun. 2019, 10, 3918.
[8] Y. Hirata, H. Nakata, K. Yamada, K. Okuhara, T. Naito, 
_Tetrahedron_ **1961**, *14*, 252–274.

[9] K. Kakinuma, C. A. Hanson, K. L. J. Rinehart, 
_Tetrahedron_ **1976**, *32*, 217–222.

[10] S. J. Moss, C. J. Martin, B. Wilkinson, 
Nat. Prod. Rep. **2004**, *21*, 575–593.

[11] a) J. He, C. Hertweck, 
*ChemBioChem* **2005**, *6*, 908–912; b) B. Busch, N. Ueberschaar, Y. Sugimoto, C. Hertweck, 
_J. Am. Chem. Soc._ **2012**, *134*, 12382–12385.

[12] Y. Koyama, Y. Fukakusa, N. Kyomura, S. Yamagishi, T. Arai, 
_Tetrahedron Lett._ **1969**, *10*, 355–358.

[13] a) M. G. Nair, A. Chandra, D. L. Thorogood, 
_J. Antibiot._ **1993**, *46*, 1762–1763; b) Y. Ishibashi, S. Nishiyama, S. Yamamura, 
_Chem. Lett._ **1994**, *23*, 1747–1748.

[14] Y. Sugimoto, L. Ding, K. Ishida, C. Hertweck, 
_Angew. Chem. Int. Ed._ **2014**, *53*, 1560–1564; 
_Angew. Chem._ **2014**, *126*, 1586–1590.

[15] M. G. Nair, Board of Trustees Operating Michigan State University, United States of America, 1994.

[16] T. Brautaset, O. N. Sekurova, H. Sletta, T. E. Ellingsen, A. R. StrLm, S. Valla, S. B. Zotchev, 
_Chem. Biol._ **2000**, *7*, 395–403.

[17] A. T. Keatinge-Clay, 
_Chem. Biol._ **2007**, *14*, 898–908.

[18] a) J. He, M. Muller, C. Hertweck, 
_J. Am. Chem. Soc._ **2004**, *126*, 16742–16743; b) M. E. Richter, N. Traitecheva, U. Knupfer, C. Hertweck, 
_Angew. Chem. Int. Ed._ **2008**, *47*, 8872–8875; 
_Angew. Chem._ **2008**, *120*, 9004–9007; c) G. Zocher, M. E. Richter, U. Mueller, C. Hertweck, 
_J. Am. Chem. Soc._ **2011**, *133*, 2292–2302.

[19] M. Richter, B. Busch, K. Ishida, B. S. Moore, C. Hertweck, 
_ChemBioChem_ **2012**, *13*, 2196–2199.

[20] M. Muller, J. He, C. Hertweck, 
_ChemBioChem_ **2006**, *7*, 37–39.

[21] B. Zhang, Z. Xu, Q. Teng, G. Pan, M. Ma, B. Shen, 
_Angew. Chem. Int. Ed._ **2017**, *56*, 7247–7251; 
_Angew. Chem._ **2017**, *129*, 7353–7357.

[22] a) T. Nguyen, K. Ishida, H. Jenke-Kodama, E. Dittmann, C. Gurgui, T. Hochmuth, S. Taudien, M. Platzer, C. Hertweck, 
_J. Piel, Nat. Biotechnol._ **2008**, *26*, 225–233; b) D. C. Gay, G. Gay, A. J. Axelrod, M. Jenner, C. Kohlhaas, A. Kampa, N. J. Oldham, 
_J. Piel, A. T. Keatinge-Clay, Structure_ **2014**, *22*, 444–451.

[23] B. Busch, N. Ueberschaar, S. Behnken, Y. Sugimoto, M. Werneburg, N. Traitecheva, J. He, C. Hertweck, 
_Angew. Chem. Int. Ed._ **2013**, *52*, 5285–5289; 
_Angew. Chem._ **2013**, *125*, 5393–5397.

[24] a) F. Del Vecchio, H. Petkovic, S. G. Kendrew, L. Low, B. Wilkinson, R. Lill, J. Cortés, B. A. Rudd, J. Staunton, P. F. Leadlay, 
_J. Ind. Microbiol. Biotechnol._ **2003**, *30*, 489–494; 
 b) K. J. Weissman, P. F. Leadlay, 
_Nat. Rev. Microbiol._ **2005**, *3*, 925–936; c) M. Klaus, M. Grining, 
_Nat. Prod. Rep._ **2018**, *55*, 1070–1081; d) D. H. Sherman, 
_Nat. Biotechnol._ **2005**, *22*, 1083–1084; e) S. Kushnir, U. Sundermann, S. Yahiou, A. Brockmeyer, P. Janning, F. Schulz, 
_Angew. Chem. Int. Ed._ **2012**, *51*, 10664–10669; 
_Angew. Chem._ **2012**, *124*, 10820–10825.

[25] W. Xu, G. Zhai, Y. Liu, Y. Li, Y. Shi, K. Hong, H. Hong, P. F. Leadlay, Z. Deng, Y. Sun, 
_Angew. Chem. Int. Ed._ **2017**, *56*, 5503–5506; 
_Angew. Chem._ **2017**, *129*, 5595–5598.

[26] N. A. Moss, T. Leão, M. R. Rankin, T. M. McCullough, P. Qu, A. Korobeynikov, J. L. Smith, L. Gerwick, W. H. Gerwick, 
_ASC Chem. Biol._ **2018**, *13*, 3385–3395.

Manuscript received: September 4, 2019
Accepted manuscript online: October 9, 2019
Version of record online: October 30, 2019